Drug profile · INN
alpelisib
VIJOICE
alpelisib (VIJOICE) is a pi3-kinase p110-alpha subunit inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — alpelisib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 7
- Data quality
- 0.84
Quick answer
alpelisib (VIJOICE) is a pi3-kinase p110-alpha subunit inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
PI3-kinase p110-alpha subunit inhibitor
Primary target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is alpelisib?
alpelisib (VIJOICE) is a pi3-kinase p110-alpha subunit inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for alpelisib?
VIJOICE is a marketed brand name for alpelisib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of alpelisib?
alpelisib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.